Abstract: Objective To investigate the cell proliferation and differentiation in the developing brain of mouse. Methods C57/BL6 mice were divided into 3 groups at random. Bromodeoxyuridine (BrdU) was injected into the brains in different development periods once a day for 7 d. The brains were retrieved 4 weeks after the last BrdU injection. Immunohistochemical and immunofluorescent studies were carried out for detecting cell proliferation (BrdU) and cell differentiation (NeuN, APC, Iba1, and S100β), respectively. Results The number of BrdU labeled cells decreased significantly with the development of the brain. Cell proliferation was prominent in the cortex and striatum. A small portion of BrdU and NeuN double labeled cells could be detected in the cortex at the early stage of development, and in the striatum and CA of the hippocampus in all groups. The majority of BrdU labeled cells were neuroglia, and the number of neuroglia cells decreased dramatically with brain maturation. Neurogenesis is the major cytogenesis in the dentate gyrus. Conclusion These results demonstrated that cell proliferation, differentiation and survival were age and brain region related.
Introduction
It is long believed that neurons are permanent cells: once damaged or dead, cannot be regenerated. However, only recently has neurogenesis become accepted as a general phenomenon in the brains of birds [1] , rodents [2] [3] [4] [5] , monkeys [6] , and humans [7] . Further studies demonstrated that neurogenesis persisted in the mammal forebrain throughout the whole life [8, 9] , and was modulated by both physiological stimuli and pathophysiological conditions [10, 11] .
However, there were no reports about the cell proliferation, migration, and differentiation under physiological conditions in the developing brain. In this study, 5-bromodeoxyuridine (BrdU) was used as an early marker of cell proliferation to examine the cell proliferation in the normal brain development. The phenotypes of proliferation cells were further identified by double immunofluorescence staining with antibodies against neuronal nuclear antigen (NeuN, a mature neuron marker), adenomatus polyposis coli (APC, oligodendrocyte marker), ionized calcium binding adapter molecule 1 (Iba1, an active microglia marker), or S100β (astrocyte marker).
Materials and methods

Experimental grouping and BrdU injection
Eighteen C57/BL6 male mice (weighing 3-5 g) were used in the present study. The mice pups of postnatal 10 d (P10) (n = 6), 17 d (P17) (n = 6) and 24 d (P24) (n = 6), corresponding to the early stage, medium stage and late stage of the brain development, were assigned randomly into 3 groups. BrdU is an analogue of thymidine, used as an early marker of cell proliferation. It works by substituting for thymidine during DNA replication and incorporating itself into the newly synthesized DNA during S-phase. BrdU (5 mg/ mL, dissolved in 0.9% saline solution; Roche, Mannheim, Germany) was injected (50 mg/kg, i.p.) once a day for 7 d from P10, P17, or P24 in different groups. The mice pups were sacrificed 4 weeks after the last injection.
immunohistochemistry staining
The animals were deeply anesthetized with 50 mg/mL phenobarbital and per-fusion-fixed with 5% formaldehyde in 0.1 mol/L PBS for 24 h. After dehydration with graded ethanol and xylene, the brains were paraffin-embedded. The serial coronal sections were cut into 5 μm and mounted on the glass slides. The serial pair-sections with an interval of 50 sections were chosen for BrdU immunohistochemistry staining. After deparaffin and dehydration, antigen recovery was performed by boiling the sections in 10 mmol/L citrate buffer (pH 6.0) for 10 min. Nonspecific binding was blocked with 4% donkey serum in PBS for 30 min. The sections were incubated with monocolonal rat anti-BrdU primary antibody (1:100, 5 μg/mL; clone: BU1/75, Oxford Biotechnology Ltd.
Oxfordshire, UK) for 60 min at room temperature, followed by biotinylated donkey anti-rat IgG (H+L) secondary antibody (1:200, 5.5 μg/mL; Jakson ImmunoResearch Lab. PA, USA) for 60 min at room temperature. Endogenous peroxidise activity was blocked with 3% H 2 O 2 in PBS for 10 min. Visualization was performed by using Vectastain ABC Elite (Vector Laboratories, Burlingame, CA, USA) with 0.5 mg/mL 3,3'-diaminobenzidine (DAB) and enhanced with 15 mg/mL ammonium nickel sulphate, 2 mg/mL β-D glucose, 0.4 mg/mL ammonium chloride and 0.01 mg/mL β-glucose oxidase (Sigma, St Louis, MO, USA).
Immunofluorescence staining
The phenotypes of newborn cells was determined by using double immunofluorescent staining. The antibodies, mouse monoclonal anti-NeuN, mouse monoclonal anti-APC, rabbit monoclonal anti-Iba1 and rabbit monoclonal anti-S100β, were used to detect mature neuron, oligodendrocyte, microglia and astrocyte, respectively. Sections deparaffin and antigen recovery was performed as above. After blocked with 4% donkey serum, the sections were incubated with rat antiBrdU monoclonal antibody (1:100, 5 μg/mL; clone: BU1/75, Oxford Biotechnology Ltd. Oxfordshire, UK) and combined with either mouse anti-NeuN monoclonal antibody (1:200, 5 μg/mL; clone: MAB377, Chemicon, Temecula, CA, USA), or mouse anti-APC monoclonal antibody (1:100, 1 μg/mL; clone: CC-1; Calbiochem, Darmstadt, Germany), or rabbit anti-Iba1 monoclonal antibody (1:1000, 0.5 μg/mL; Wako, Osaka, Japan), or rabbit anti-S100β (1:1000; Swant, Bellinzona, Switzerland) in PBS at room temperature for 60 min. After washing, the sections were incubated with the secondary antibody Alexa Fluor 488 donkey anti-rat IgG (H+L) (1:150; Molecular Probes, USA) combined with either Alexa Fluor 555 donkey anti-mouse IgG (H + L) (1:150; Molecular Probes, USA) for BrdU/NeuN and BrdU/APC, or with Alexa Fluor 555 donkey anti-rabbit IgG (H+L) (1: 150; Molecular Probes, USA) for BrdU/Iba1 and BrdU/S100β at room temperature for 60 min. After washing again, the sections were mounted by Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Immunofluorescent-stained sections were analyzed by using stereological system (Leica DM6000 M, Leica Microsystems Wetzlar GmbH, Germany) and laser-scanning confocal microscopy (Leica TCS, SP2, Leica Microsystems, Heidelberg, Germany).
Cell counting
BrdU-positive cells were counted in the cortex, striatum, and the hippocampal regions: cornu ammonis (CA) and gyrus dentatus (DG). The areas were measured by stereological system [12] . Positive cells of each area were counted in each section of the brain and expressed as an average number of cells per mm 3 .
Statistics
All data were expressed as mean ± SD. ANOVA with Fisher's post-hoc test was used when more than two groups were compared. Differences were considered significant at P < 0.05.
Results
Cell proliferation in the developing brain Using
BrdU as a marker for cell proliferation, newly generated survival cells were detected by immunohistochemistry staining. Figure 1 (A-I) showed the typical distributions of BrdU labeled cells in the cerebral cortex, striatum, CA and DG in three groups. Quantitative analysis of BrdU-positive cells within different age group was indicated in Fig. 1J . The number of BrdU labelled cells (the newborn cells) of each group decreased with the development of the brain (Fig. 1) . The number of BrdU labelled cells in the P17-23 group decreased dramatically compared with that in the P10-16 group (P < 0.001) and there was no obvious change afterwards (Fig. 1A-C, J) in the cortex. The cell proliferation in the striatum, CA and DG decreased with brain maturation, similar to that in the cortex (Fig. 1D-I, J) . Comparing the BrdU labelled cells in the different areas, we found that cell proliferation in the cortex markedly increased in the P10-16 group. In the striatum, DG and CA, the number of BrdU labelled cells decreased more and more. With the brain gradually maturing, the distribution of the newborn cells went to stabilization (Fig. 1J) .
Neurogenesis in the developing brain
NeuN is a mature-neuron specific nuclear protein. BrdU/NeuN double label immunofluorescence assay was to evaluate how many newborn cells differentiated into mature neurons. Figure 2A showed the representative BrdU/NeuN immunofluorescence staining. Figure 3A showed quantitative analysis of neurogenesis in developing brain. In cortex, the new neurons were detected only in P10-16 group, and the cell density was (47±18) mm 3 . In the striatum, the double positive cells can be detected in all groups, no significant change among them. However, the double positive cells dramatically increased in the DG in P10-16 group with the cell density of (539±145) mm 3 , and decreased to (282±57) mm 3 and (161±27) mm 3 in the P17-23 group and the P24-30 group, respectively (P < 0.001). Comparing the neurogenesis in the different areas, we found that the new neurons in the DG were much more than that in the other areas. No significant change was observed among the other areas. 16 group) . Moreover, the ratio of BrdU/APC and BrdU/ Iba1 was much higher than that of BrdU/S100β, indicating that APC-(oligodendrocyte) and Iba1-(microglia) positive cells were dominant in the new generated cells. The number of these glial cells decreased significantly with brain maturation in both cortex and striatum, and the reduction was much more pronounced for the Iba1 (microglia) -positive cells (Fig. 3B-D) . In the cortex, the new produced microglia in P10-16 group was 22 times higher than that in P17-23, and 16 times higher than that in P24-30. In the striatum, it was 14 times and 24 times higher than that in P17-23 and P24-30 group, respectively. The double labelling of BrdU and glia markers in the hippocampus as indicated ( Fig. 3B-D) . In the early term of brain development (P10-16 group), the number of BrdU/Iba1 markedly increased and declined thereafter in the CA area. However, no newly generated microglia was detected in the late stage of brain development (P24-30 group). No significant changes of BrdU/APC (oligodendrocyte) and BrdU/S100β (astrocyte) were observed among the stages of brain development. In DG, the number of BrdU labelled astrocyte decreased significantly with brain maturation (P < 0.01). However, there were no significant changes of microglia and oligodendrocyte during the whole period of brain development.
Gliogenesis in the developing brain
Discussion
The current study demonstrated that neurogenesis persists in the brain throughout the life, and the rate of neuronal production declined with age [8] . However, there was no report to show when the cell proliferation start to decline. This study showed that the cell proliferation, migration and survival was much higher at P10-16 and declined dramatically after that in the developing brain. Although very little is known about the exact molecular mechanisms that regulate neural stem cell proliferation, several factors have been identified to affect neurogenesis. Endogenously synthesized basic fibroblast growth factor (bFGF) stimulates neurogenesis in the subventricular zone (SVZ). The mice's genetical deficiency in bFGF exhibit a significant reduction of neurogenesis [13, 14] . Heparin-binding epidermal growth factor (HB-EGF) can stimulate the neurogenesis [15] . Furthermore, the increase of brain-derived neurotrophic factor (BDNF), erythropoietin, or EGF may augment neurogenesis [16] [17] [18] . These data suggest that a variety of neurotrophic and growth factors can stimulate neurogenesis. In this study, the number of newborn cells that labelled by mature-neuron marker NeuN was higher at P10-16, corresponding to the early stage of the brain development. Some researches has demonstrated that many growth factors are expressed at high levels in the developing brain and decreased when the brain development completed [19, 20] . Moreover, our study also found that in the early development stage, the cytogenesis varied in different areas of the brain. Cell proliferation was most active in the cortex and striatum, and least active in the CA area, suggesting that the proliferation of new cells is related with the microenvironment they encountered. Neurogenesis in the cerebral cortex was discrepancy. Gould et al. [21] reported the genesis of new neurons in the neocortex of adult macaque monkeys. These cells arise from the SVZ and migrate through the white matter to integrate into the neocortex, where they differentiate into mature neurons. However, another study performed in macaque was not in agreement with these data and, in contrast, demonstrated that BrdU positive cells detected in the neocortex are in fact satellite glial cells closely apposed to resident neurons [22] . In the developing brain, neurogenesis has been identified in the cortex [23] . In this study, very little BrdU and NeuN double positive cells were detected in the cortex at P10-16 and no double positive cell was detected at P17-23 and P24-30. However, in striatum, CA and DG areas, the double positive cells can be detected in all the groups. Especially in DG, most newly produced cells differentiated into the neurons. Moreover, the neurogenesis was pronounced at P10-16 and decreased with the development of the brain. The age-related decline in neurogenesis is due to the rate of neuronal production declines with age and age related alteration in the cellular microenvironment slow the neuron maturation [24] . It indicates that the immature brain possess much potential capacity to generate new neurons.
Although our study demonstrated that there was neurogenesis in the cortex, striatum and CA, the total number of BrdU and NeuN double positive cells was very low. On the contrary, majority BrdU labeled cells were stained with Iba1 (microglia) or APC (oligodendrocyte). The large amount of microglia cells probably enhances neural stem cell proliferation and migration [25] . The oligodendrocyte may indicate that myeline formation is under an active stage in the neonates [26] . It indicates that the younger the more plasticity is possessed. Astrocytes play many essential roles in normal neurotransmission [27] , but astrogenesis was relatively low in our study. In summary, the present study demonstrates that the cell proliferation, differentiation and survival were age and brain region related. Brain developmental level needs to be concerned for the future study and clinical intervention.
